Radiotherapy & Oncology
Volume 93, Issue 2 , Pages 185-191 , November 2009

Radical prostatectomy vs. intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma

  • Ayal A. Aizer

      Affiliations

    • Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, USA
    • Corresponding Author InformationCorresponding author. Address: Department of Therapeutic Radiology, Yale School of Medicine, PO Box 208040, New Haven, CT 06510, USA.
    • ,
  • James B. Yu

      Affiliations

    • Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, USA
    • ,
  • John W. Colberg

      Affiliations

    • Section of Urology, Department of Surgery, Yale School of Medicine, New Haven, CT, USA
    • ,
  • Anne M. McKeon

      Affiliations

    • Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, USA
    • ,
  • Roy H. Decker

      Affiliations

    • Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, USA
    • ,
  • Richard E. Peschel

      Affiliations

    • Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, USA

Received 15 May 2009 ,Revised 25 August 2009 ,Accepted 1 September 2009.

References 

  1. Peschel RE, Colberg JW. Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. Lancet Oncol. 2003;4:233–241
  2. Paulson DF, Lin GH, Hinshaw W, Stephani S. Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol. 1982;128:502–504
  3. Hanks GE. More on the Uro-Oncology Research Group report of radical surgery vs. radiotherapy for adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1988;14:1053–1054
  4. Repetto L, Granetto C, Hall RR. Prostate cancer. Crit Rev Oncol Hematol. 1998;27:145–146
  5. Byhardt RW, Greenlaw RH, Jensen R, et al. Re: radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol. 1983;130:1205–1206
  6. Keyser D, Kupelian PA, Zippe CD, Levin HS, Klein EA. Stage T1–2 prostate cancer with pretreatment prostate-specific antigen level < or =10 ng/ml: radiation therapy or surgery?. Int J Radiat Oncol Biol Phys. 1997;38:723–729
  7. D’Amico AV, Whittington R, Kaplan I, et al. Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of >4–20ng/ml. Int J Radiat Oncol Biol Phys. 1997;37:1053–1058
  8. D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974
  9. Martinez AA, Gonzalez JA, Chung AK, et al. A comparison of external beam radiation therapy versus radical prostatectomy for patients with low risk prostate carcinoma diagnosed, staged, and treated at a single institution. Cancer. 2000;88:425–432
  10. Kupelian PA, Elshaikh M, Reddy CA, Zippe C, Klein EA. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol. 2002;20:3376–3385
  11. Kupelian PA, Potters L, Khuntia D, et al. Radical prostatectomy, external beam radiotherapy <72Gy, external beam radiotherapy > or =72Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancer. Int J Radiat Oncol Biol Phys. 2004;58:25–33
  12. Potters L, Klein EA, Kattan MW, et al. Monotherapy for stage T1–T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol. 2004;71:29–33
  13. D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer. 2002;95:281–286
  14. Cahlon O, Hunt M, Zelefsky MJ. Intensity-modulated radiation therapy: supportive data for prostate cancer. Semin Radiat Oncol. 2008;18:48–57
  15. Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 2001;166:876–881
  16. Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol. 2006;176:1415–1419
  17. D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008;299:289–295
  18. D’Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292:821–827
  19. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295–300
  20. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360:103–106
  21. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50:1243–1252
  22. Roach M, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008;26:585–591
  23. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005;61:1285–1290
  24. Thames H, Kuban D, Levy L, et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys. 2003;57:929–943
  25. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–974
  26. Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177:540–545
  27. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002.
  28. Zelefsky MJ, Hollister T, Raben A, Matthews S, Wallner KE. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2000;47:1261–1266
  29. Zelefsky MJ, Wallner KE, Ling CC, et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol. 1999;17:517–522
  30. Gilbert EH, Lowenstein SR, Koziol-McLain J, Barta DC, Steiner J. Chart reviews in emergency medicine research: where are the methods?. Ann Emerg Med. 1996;27:305–308
  31. Klein JP, Logan B, Harhoff M, Andersen PK. Analyzing survival curves at a fixed point in time. Stat Med. 2007;26:4505–4519
  32. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766–771
  33. Frank SJ, Levy LB, Kuban DA, et al. Prostogram predicted brachytherapy outcomes are not universally accurate: an analysis based on the M.D. Anderson Cancer Center experience with (125)iodine brachytherapy. J Urol. 2009;181:1658–1663[discussion 1663–1654]
  34. Kuban DA, Thames HD, Levy LB, et al. Long-term multi-institutional analysis of stage T1–T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2003;57:915–928
  35. Kattan MW, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z, Leibel SA. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol. 2000;18:3352–3359
  36. Pollack A, Zagars GK, Smith LG, et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70Gy with 78Gy for prostate cancer. J Clin Oncol. 2000;18:3904–3911
  37. Nielsen ME, Makarov DV, Humphreys E, Mangold L, Partin AW, Walsh PC. Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion – “nadir+2”?. Urology. 2008;72:389–393[discussion 394–385]

PII: S0167-8140(09)00498-8

doi: 10.1016/j.radonc.2009.09.001

Radiotherapy & Oncology
Volume 93, Issue 2 , Pages 185-191 , November 2009

Article Tools

* Image Usage & Resolution